Thyroid cancer is the most common endocrine cancer. Neurotrophic tyrosine receptor kinase
(NTRK) fusions are oncogenic drivers in multiple solid tumors, including thyroid cancer …

Purpose Pathogenic fusion events involving neurotrophic receptor tyrosine kinase (NTRK)
have been described in~ 2% of differentiated thyroid cancer (DTC). The selective …

Importance Thyroid epithelial malignant neoplasms include differentiated thyroid
carcinomas (papillary, follicular, and oncocytic), follicular-derived high-grade thyroid …

The tropomyosin receptor kinase (Trk) receptors, TrkA, TrkB, and TrkC, encoded by the
NTRK1, NTRK2, and NTRK3 genes, respectively, are transmembrane proteins that play an …

Objective Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with
demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the …

Background Larotrectinib is a first-in-class, central nervous system-active, highly selective
tropomyosin receptor kinase (TRK) inhibitor approved by the EMA and FDA for the treatment …

Objectives: NTRK gene fusions are oncogenic drivers in many solid tumours, including
thyroid cancers. In the phase 2 study STARTRK-2 (NCT02568267), entrectinib (a CNS …

Objective The aim of the study was to identify patients with NTRK fusion-positive or RET
fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine …

NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types,
including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor …

Owing to the availability of a potent tropomyosin receptor kinase (TRK) inhibitor, it is
necessary to develop an effective strategy to identify an enriched population of NTRK …